Yup.
And distinguishing it without different evidence-based treatment? Just adds a layer of stigma that hasn’t helped in other forms of mental illness with poor treatment prognosis (specifically when we’re talking about the DSM). Complex ptsd would become ‘the ptsd that can’t treated’, and the people labelled with it get burdened with that.
If the best evidence-based treatment currently available for cptsd is the same as the evidence-based treatment currently available for ptsd (which it is, right?)…then, steer clear of the label that differentiates you as ‘the group that doesn’t respond well to treatment’!
This will change. I think we’re getting there slowly. But not there yet. And I think the treatments will be more effective if we can do better than the just the simple/complex dichotomy.
I completely agree with your perspective. However, in the U.S., many individuals with PTSD have already fought and continue to fight the strong stigma associated with their diagnosis. And fighting that of CPTSD would merely be an extension of that, IMO
What people are asking for is not to create further diagnostic division, but to be seen. Recognition, as it exists in much of the world through the ICD-11, would allow CPTSD to be included in the curriculum of higher education and professional training programs. This visibility would engage more students, researchers, and clinicians, fostering new innovative perspectives, treatment modalities, and even potentially new pharmacological interventions designed specifically to address the impacts of complex trauma.
While I absolutely agree that stigma remains a major societal challenge, millions of Americans meet criteria for CPTSD under the ICD framework and are seeking care tailored to their needs. These individuals have often experienced prolonged or repeated exposure to trauma, frequently across multiple domains, including Adverse Childhood Experiences (ACEs).
Yet, the first-line PTSD treatments currently available in the U.S., such as Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR) are primarily designed for single-incident trauma. For many with CPTSD, these modalities do not adequately address the complex interplay of emotional regulation, self-concept, and relational difficulties that define this distinct disorder.
Additionally, clinician proficiency and training gaps remain significant barriers to effective care in the U.S. This lack of proficiency in tailoring PTSD treatments to the needs of CPTSD patients largely stems from two issues: (1) limited institutional education on CPTSD, which results from its lack of national recognition, and (2) the continued reliance on single-event trauma models in therapy, again a direct consequence of the absence of formal diagnostic inclusion here.
There is, however, growing support for research into innovative interventions particularly psychedelic-assisted therapies using substances such as MDMA and ibogaine which have shown potential to enhance neuroplasticity and recalibrate physiological fear responses. I have personally witnessed promising outcomes in a colleague who traveled abroad to receive such treatment and returned with profound and sustained improvement. I’m genuinely curious to hear thoughts and experiences from this highly knowledgeable and thoughtful community here. Best!